Maegim한국어

아이티켐

309710KOSDAQSector: Pharma & Biotech
₩21,000 0.00%Market cap ₩268.4BAs of Jul 21, 2026 close · updated once daily
D
Grade D28.6 ptsTop 88% of 2,523 stocks
Financial strength
26.4
Price attractiveness
31.1

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

Growth momentum not rated — will be included automatically as data accumulates

1

Financial strength

26.4
How much debt does it carry relative to equity?
Debt-to-equity ratio
177.3%
Below median · Top 88.8% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
66.5%
Below median · Top 86.8% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
-3.0%
Below median · Top 51.2% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
-21.9%
Below median · Top 67.7% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original

3

Price attractiveness

31.1
Is the price expensive relative to earnings?
P/E (price-to-earnings)
Loss-making (P/E not computable)
Below median · Top 63.2% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
4.11x
Below median · Top 74.6% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15